Skip to main content

AFFIRM: A Randomized, double-blind, placebo-controlled, study to evaluate the effect of Seladelpar on clinical outcomes in patients with primary biliary cholangitis (PBC) and compensated cirrhosis.

Open
  • Protocol code: CB8025-41837
  • EudraCT code: _
  • Research group: Liver Diseases
  • Service: Hepatology
  • Principal investigator:  Villagrasa Vilella, Ares Aurora
  • Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
  • Phase: Fase III